The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of gemcitabine (Gem)-based palliative first-line therapy in the treatment of recurrent disease or of initially unresectable pancreatic cancer (PC).
 
Sina Rosenblender
No Relationships to Disclose
 
Jens Stieler
Honoraria - Amgen; Roche Pharma AG
Travel, Accommodations, Expenses - Amgen; Roche Pharma AG
 
Sven Bischoff
No Relationships to Disclose
 
Marianne Sinn
Honoraria - Braun Travacare; Celgene; LEO Pharma; Roche Pharma AG
Travel, Accommodations, Expenses - Bayer
 
Uwe Pelzer
Research Funding - Amgen (Inst); Braun Travacare (Inst); Celgene (Inst); Roche Pharma AG (Inst)
 
Jana Kaethe Striefler
No Relationships to Disclose
 
Bernd Dörken
No Relationships to Disclose
 
Hanno Riess
Consulting or Advisory Role - Bayer; Celgene; GlaxoSmithKline; Roche Pharma AG
Speakers' Bureau - Bayer; Celgene; GlaxoSmithKline; Roche Pharma AG